The purpose of this study is to determine whether fenofibrate effects the toleration, safety,
or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.
- BMI of 30-40 kg/m2
- Women of childbearing potential
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center
Pfizer Clinical Trials Contact Center
call now email
Contact a representative by phone, email, or visiting the study website. Please see the references below: